Keywords: gene, variant, reduces, plavix, effectiveness, shares, sanofi-aventis
Gene variant reduces Plavix effectiveness
Article | 12 January 2009
Shares in Sanofi-Aventis dropped 4.3% to 44.50 euros on December 23, 2008, after three separate studies identified a genetic variant that impairs patient response ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
